choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • MannKind Diabetes

MannKind Diabetes Newsletter
  • MannKind Repays Certain Debt Obligations 03 Apr 2024 10:00 GMT

    … over two million shares.” About MannKind MannKind Corporation (Nasdaq: MNKD) focuses … burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) … a registered trademark of MannKind Corporation. For MannKind:         Christie Iacangelo, …

  • Diabetes Dialogue: What to Know about Sequel Med Tech's twiist AID System, with Alan Lotvin, MD 30 Mar 2024 20:14 GMT

    … program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and … for Dr. Bellini include Abbott Diabetes Care, MannKind, Sanofi, and others. References …

  • Diabetes Dialogue: Hot Topics and Updates from ATTD 2024 30 Mar 2024 17:08 GMT

    … Technologies & Treatments for Diabetes, hosts of Diabetes Dialogue: Technology, Therapeutics, … the session brought practitioners and diabetes care and education specialists … Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …

  • Diabetes Dialogue: All Things AID at ATTD 2024 29 Mar 2024 01:28 GMT

    … director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … Technologies & Treatments for Diabetes, including updates from Insulet Corporation … for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …

  • Hybrid closed-loop may be more cost-effective than immune therapies for type 1 diabetes 27 Mar 2024 17:36 GMT

    … adverse events management, diabetes management and management of diabetes-related complications. Treatment … Haller reports receiving honoraria from Mannkind, Mediflix and Sanofi; serving … an adviser or consultant for Mannkind and Sanofi; receiving research …

  • MannKind Announces CFO Transition 26 Mar 2024 20:05 GMT

    … Kelley School of Business. About MannKind MannKind Corporation (Nasdaq: MNKD) focuses … burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) … a registered trademark of MannKind Corporation. For MannKind:         Christie Iacangelo, …

  • Diabetes Dialogue: FLOW Trial and Chronic Kidney Disease Updates, with Brendon Neuen, MBBS, PhD 22 Mar 2024 01:15 GMT

    … meeting. In this episode of Diabetes Dialogue: Technology, Therapeutics, & … , program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care … for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …

  • Diabetes Dialogue: Stelo News and Dexcom CGM Updates, with Jake Leach 20 Mar 2024 21:21 GMT

    … other Dexcom products, hosts of Diabetes Dialogue: Technology, Therapeutics, & … Advanced Technologies & Treatments for Diabetes (ATTD) 2022, where Leach discussed … for Dr. Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others …

  • Glucose Changes in Type 1 Diabetes May Affect Thinking Speed 20 Mar 2024 15:32 GMT

    … Recentlyheard In kind 1 diabetes, glucose fluctuations had … result of individuals with diabetes usually report feeling … via use of automated diabetes administration methods.” In … Nordisk, Insulet, Tandem, Amgen, MannKind, Diasome, DexCom, Medtronic, and …

  • Use both HbA1c, CGM metrics for optimal diabetes management 11 Mar 2024 17:23 GMT

    … prevent complications in patients with diabetes,” Selvin said during the presentation … al. Parallel session 02: CGM diabetes quality measures. Presented at: International … research support from Dexcom, MannKind and Tandem Diabetes Care; and serving as …

Satisfied with the content?

Continue to create your account.